MURAL ONCOLOGY PLC (MURA) Fundamental Analysis & Valuation

NASDAQ:MURA • IE000LK2BOB4

2.04 USD
0 (0%)
At close: Dec 4, 2025
2.03 USD
-0.01 (-0.49%)
After Hours: 12/4/2025, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This MURA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

MURA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 520 industry peers in the Biotechnology industry. MURA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MURA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. MURA Profitability Analysis

1.1 Basic Checks

  • MURA had negative earnings in the past year.
  • MURA had a negative operating cash flow in the past year.
MURA Yearly Net Income VS EBIT VS OCF VS FCFMURA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

  • With a Return On Assets value of -181.12%, MURA is not doing good in the industry: 88.70% of the companies in the same industry are doing better.
  • With a Return On Equity value of -215.81%, MURA is not doing good in the industry: 70.24% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -181.12%
ROE -215.81%
ROIC N/A
ROA(3y)-235.67%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MURA Yearly ROA, ROE, ROICMURA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 -2K -4K -6K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for MURA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MURA Yearly Profit, Operating, Gross MarginsMURA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. MURA Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, MURA has more shares outstanding
  • MURA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MURA Yearly Shares OutstandingMURA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5M 10M 15M
MURA Yearly Total Debt VS Total AssetsMURA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • MURA has an Altman-Z score of -7.55. This is a bad value and indicates that MURA is not financially healthy and even has some risk of bankruptcy.
  • MURA has a worse Altman-Z score (-7.55) than 68.74% of its industry peers.
  • There is no outstanding debt for MURA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.55
ROIC/WACCN/A
WACCN/A
MURA Yearly LT Debt VS Equity VS FCFMURA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

  • MURA has a Current Ratio of 5.90. This indicates that MURA is financially healthy and has no problem in meeting its short term obligations.
  • MURA has a better Current ratio (5.90) than 61.21% of its industry peers.
  • A Quick Ratio of 5.90 indicates that MURA has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 5.90, MURA is in the better half of the industry, outperforming 62.52% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.9
Quick Ratio 5.9
MURA Yearly Current Assets VS Current LiabilitesMURA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. MURA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 24.16% over the past year.
EPS 1Y (TTM)24.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.77%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • MURA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.94% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y23.84%
EPS Next 2Y39.55%
EPS Next 3Y25.65%
EPS Next 5Y11.94%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MURA Yearly Revenue VS EstimatesMURA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 100M 200M 300M
MURA Yearly EPS VS EstimatesMURA Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

1

4. MURA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MURA. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MURA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MURA Price Earnings VS Forward Price EarningsMURA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MURA Per share dataMURA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6

4.3 Compensation for Growth

  • MURA's earnings are expected to grow with 25.65% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.55%
EPS Next 3Y25.65%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MURA Dividend Analysis

5.1 Amount

  • No dividends for MURA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MURA Fundamentals: All Metrics, Ratios and Statistics

MURAL ONCOLOGY PLC

NASDAQ:MURA (12/4/2025, 8:00:02 PM)

After market: 2.03 -0.01 (-0.49%)

2.04

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)N/A
Inst Owners42.85%
Inst Owner ChangeN/A
Ins Owners2.2%
Ins Owner Change-14.74%
Market Cap35.37M
Revenue(TTM)N/A
Net Income(TTM)-119.10M
Analysts43.33
Price Target6.12 (200%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)18.17%
Min EPS beat(2)-28.77%
Max EPS beat(2)65.1%
EPS beat(4)2
Avg EPS beat(4)10.8%
Min EPS beat(4)-28.77%
Max EPS beat(4)65.1%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)65.42%
EPS NY rev (1m)0%
EPS NY rev (3m)7.31%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.64
P/tB 0.64
EV/EBITDA N/A
EPS(TTM)-5.91
EYN/A
EPS(NY)-0.4
Fwd EYN/A
FCF(TTM)-6.83
FCFYN/A
OCF(TTM)-6.83
OCFYN/A
SpS0
BVpS3.18
TBVpS3.18
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -181.12%
ROE -215.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-235.67%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.04%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.9
Quick Ratio 5.9
Altman-Z -7.55
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)167.92%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)24.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.77%
EPS Next Y23.84%
EPS Next 2Y39.55%
EPS Next 3Y25.65%
EPS Next 5Y11.94%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y34.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year27.74%
EBIT Next 3Y25.8%
EBIT Next 5Y8.57%
FCF growth 1Y34.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y33.82%
OCF growth 3YN/A
OCF growth 5YN/A

MURAL ONCOLOGY PLC / MURA FAQ

What is the fundamental rating for MURA stock?

ChartMill assigns a fundamental rating of 2 / 10 to MURA.


Can you provide the valuation status for MURAL ONCOLOGY PLC?

ChartMill assigns a valuation rating of 1 / 10 to MURAL ONCOLOGY PLC (MURA). This can be considered as Overvalued.


Can you provide the profitability details for MURAL ONCOLOGY PLC?

MURAL ONCOLOGY PLC (MURA) has a profitability rating of 0 / 10.


How financially healthy is MURAL ONCOLOGY PLC?

The financial health rating of MURAL ONCOLOGY PLC (MURA) is 6 / 10.